These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27252317)

  • 21. Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection.
    Cheng CH; Lin CC; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
    PLoS One; 2018; 13(2):e0191799. PubMed ID: 29389957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Scale-up of hepatitis C treatment in prisons is key to national elimination.
    Papaluca T; Hellard ME; Thompson AJV; Lloyd AR
    Med J Aust; 2019 May; 210(9):391-393.e1. PubMed ID: 30968417
    [No Abstract]   [Full Text] [Related]  

  • 23. Treating hepatitis C in the prison population is cost-saving.
    Tan JA; Joseph TA; Saab S
    Hepatology; 2008 Nov; 48(5):1387-95. PubMed ID: 18924228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HCV infected prisoners: should they be still considered a difficult to treat population?
    Iacomi F; Iannicelli G; Franceschini A; Migliorisi P; Rosati S; Piselli P; Scognamiglio P; De Carli G; Marcellini S; Palmieri F
    BMC Infect Dis; 2013 Aug; 13():374. PubMed ID: 23945309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are we nearing the end in the fight against hepatitis C?
    Chua JV; Kottilil S
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):499-500. PubMed ID: 28335650
    [No Abstract]   [Full Text] [Related]  

  • 26. Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C.
    Boonwaat L; Haber PS; Levy MH; Lloyd AR
    Med J Aust; 2010 May; 192(9):496-500. PubMed ID: 20438418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002-2016.
    Marco A; Guerrero RA; Vergara M; Gallego C; Solé C; Planella R; Vaz ME; Teixidó N; Sastre A; Touzón C; da Silva A; Almada G; Ruíz A; Caylà JA; Turu E
    Int J Drug Policy; 2019 Oct; 72():189-194. PubMed ID: 31160156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings.
    Chen CP; Cheng CY; Zou H; Cheng CH; Cheng SH; Chen CK; Chen CH; Bair MJ
    J Microbiol Immunol Infect; 2019 Aug; 52(4):556-562. PubMed ID: 30360951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-life experience of hepatitis C treatment in a Spanish prison.
    Tejera-Pérez RJ; Iglesias-Gómez A; Oliva-Oliva A; Rodríguez-Alonso B; Alonso-Sardón M; Sánchez Ledesma M; Carbonell-Muñoz C; Pendones Ulerio J; Muñoz-Bellido JL; Belhassen-García M
    Rev Esp Quimioter; 2022 Jun; 35(3):273-278. PubMed ID: 35441836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study.
    Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B;
    Clin Infect Dis; 2022 Nov; 75(10):1809-1819. PubMed ID: 35362522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of antiviral therapy in Egyptian Hepatitis C Virus (HCV) genotype 4 patients with advanced liver fibrosis.
    el-Khattib AA; Abdelhakam SM; Ghoraba DM; Ibrahim WA; Sayed MM
    Eur J Intern Med; 2012 Jan; 23(1):e34-5. PubMed ID: 22153547
    [No Abstract]   [Full Text] [Related]  

  • 32. Hepatitis C: An Eastern Perspective.
    Dan YY; Lim SG
    Gastroenterol Clin North Am; 2015 Dec; 44(4):793-805. PubMed ID: 26600220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addressing Hepatitis C in the American Incarcerated Population: Strategies for Nationwide Elimination.
    Ocal S; Muir AJ
    Curr HIV/AIDS Rep; 2020 Feb; 17(1):18-25. PubMed ID: 31933274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting].
    Saiz de la Hoya-Zamácola P; Marco-Mouriño A; Clemente-Ricote G; Portilla-Sogorb J; Boix-Martínez V; Núñez-Martínez O; Reus-Bañuls S; Teixidó i Pérez N
    Enferm Infecc Microbiol Clin; 2006 Nov; 24(9):568-75. PubMed ID: 17125677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.
    Lafferty L; Rance J; Grebely J; Lloyd AR; Dore GJ; Treloar C;
    J Viral Hepat; 2018 Dec; 25(12):1526-1532. PubMed ID: 30141261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP.
    Martinot-Peignoux M; Roudot-Thoraval F; Mendel I; Coste J; Izopet J; Duverlie G; Payan C; Pawlotsky JM; Defer C; Bogard M; Gerolami V; Halfon P; Buisson Y; Fouqueray B; Loiseau P; Lamoril J; Lefrere JJ; Marcellin P
    J Viral Hepat; 1999 Nov; 6(6):435-43. PubMed ID: 10607261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current and Evolving Treatments of Genotype 1 Hepatitis C Virus.
    Alqahtani S; Sulkowski M
    Gastroenterol Clin North Am; 2015 Dec; 44(4):825-43. PubMed ID: 26600222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of IL28B Genotype in HCV-RNA Baseline Levels.
    Boglione L; Cusato J; Di Perri G; D'Avolio A
    Intervirology; 2016; 59(2):67-68. PubMed ID: 27603672
    [No Abstract]   [Full Text] [Related]  

  • 39. Enhancing hepatitis C treatment in the custodial setting: a national roadmap.
    Mina MM; Clark PJ; Beasley HM; Herawati L; Butler TG; Lloyd AR
    Med J Aust; 2014 Jan; 200(1):15-6. PubMed ID: 24438398
    [No Abstract]   [Full Text] [Related]  

  • 40. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes.
    Hnatyszyn HJ
    Antivir Ther; 2005; 10(1):1-11. PubMed ID: 15751759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.